FindTrial
Sign In

LY3437943

DRUG13 trials

Sponsors

Eli Lilly and Company

Conditions

Diabetes Mellitus, Type 2HealthyHepatic InsufficiencyObesityOverweightRenal InsufficiencyType 2 Diabetes

Phase 1

A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
CompletedNCT03841630
Eli Lilly and CompanyHealthy
Start: 2019-03-13End: 2019-07-25Updated: 2019-08-06
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
CompletedNCT04143802
Eli Lilly and CompanyDiabetes Mellitus, Type 2
Start: 2019-12-18End: 2020-12-28Updated: 2021-01-20
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)
CompletedNCT04823208
Eli Lilly and CompanyDiabetes Mellitus, Type 2
Start: 2021-05-24End: 2022-06-23Updated: 2022-08-22
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
CompletedNCT05445232
Eli Lilly and CompanyObesity
Start: 2022-07-08End: 2023-02-24Updated: 2023-04-18
A Study of LY3437943 in Chinese Participants With Obesity Or Overweight
CompletedNCT05548231
Eli Lilly and CompanyObesity, Overweight
Start: 2022-10-24End: 2023-07-27Updated: 2023-08-14
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
CompletedNCT05611957
Eli Lilly and CompanyHealthy, Renal Insufficiency
Start: 2022-11-16End: 2023-09-05Updated: 2023-10-02
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
CompletedNCT05916560
Eli Lilly and CompanyHealthy, Hepatic Insufficiency
Start: 2023-07-13End: 2025-03-02Updated: 2025-04-18
A Study of LY3437943 in Healthy Participants With a High Body Mass Index
CompletedNCT05959096
Eli Lilly and CompanyHealthy
Start: 2023-07-18End: 2024-07-25Updated: 2024-10-01
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
CompletedNCT06003465
Eli Lilly and CompanyHealthy
Start: 2023-08-29End: 2024-02-08Updated: 2024-03-29
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
CompletedNCT06039826
Eli Lilly and CompanyOverweight
Start: 2023-09-12End: 2024-07-11Updated: 2024-07-26
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
CompletedNCT06313528
Eli Lilly and CompanyObesity
Start: 2024-03-20End: 2025-08-26Updated: 2025-09-23

Phase 2

A Study of LY3437943 in Participants With Type 2 Diabetes
CompletedNCT04867785
Eli Lilly and CompanyType 2 Diabetes
Start: 2021-05-13End: 2022-10-27Updated: 2023-07-03
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
CompletedNCT04881760
Eli Lilly and CompanyObesity, Overweight
Start: 2021-05-20End: 2022-11-22Updated: 2023-09-13

Related Papers

Development of the Weight and Emotions Scale (WES).
2026-01-25
Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity.
2025-11-07
Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.
2025-10-241 citations
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
2025-06-306 citations
Subgroup analysis by sex and baseline <scp>BMI</scp> in people with a <scp>BMI</scp> ≥27 kg/m <sup>2</sup> in the phase 2 trial of survodutide, a glucagon/ <scp>GLP</scp> ‐1 receptor dual agonist
Diabetes Obesity and Metabolism2025-01-165 citations
Reduction of triglyceride-rich lipoproteins with retatrutide in type 2 diabetes may be explained by concurrent reduction in ANGPTL3/8 levels
European Heart Journal2024-10-01
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
2024-06-10131 citations
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine2023-06-26812 citations
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
2023-06-26241 citations
The novel <scp>GIP</scp> , <scp>GLP</scp> ‐1 and glucagon receptor agonist retatrutide delays gastric emptying
Diabetes Obesity and Metabolism2023-06-1322 citations
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
2022-10-27126 citations